The combined anti-PD-1 and anti-CTLA-4 antibodies group and the combined oral administration of B. longum 420 with anti-PD-1 and anti-CTLA-4 antibodies group both showed significantly suppressed tumor growth compared to the PBS group at day 21 (p < 0.05) (Fig. 3b). The gene discussed is CTLA4; the disease is neoplasm.